The article examined treatment options available for pulmonary arterial hypertension (PAH), a type of pulmonary hypertension characterized by vascular remodeling of the pulmonary arteries. If left untreated, PAH can lead to right ventricular failure and death. The supplement discussed the complexity of patients with this condition, as well as the need for providers to develop individualized treatment plans for patients with this condition. A wide variety of treatment options exist, and the appropriate choice of therapy may be based on a patient’s stage of diagnosis, an assessment of disease severity, and individual characteristics. The main objective of the article was to support the claim that, in order to continue to provide optimal care and minimize the burden of disease progression for PAH patients, it is critical for providers to maintain open access to treatments and make tailored treatment decisions for individual patients.

Avalere partnered with Actelion Pharmaceuticals to develop this report over the course of several months. Dr. Kristin Highland of the Cleveland Clinic co-authored the supplement and provided rich clinical expertise on PAH treatment approaches.

Access the full article.

To receive Avalere updates, connect with us.